Close

Jump to:

  • Navigation
  • Content
  • Footer
Thalamos hero image

Thalamos

Follow

Thalamos exists to solve digital challenges facing mental health: Product 1: Software for Psychiatrists

165%
 - 
Funded 1 Feb 2019
£100,010 target
£171,548 from 206 investors
More
Less

Business overview

Location London, United Kingdom
Social media
Website www.thalamos.co.uk
Sectors Healthcare Digital Mixed B2B/B2C
Company number 10814088
Incorporation date 12 Jun 2017
More
Less

Investment summary

Type Equity
Valuation (pre-money) £1.5M
Equity offered 9.92%
Tax relief

EIS

  • Idea
  • Team
  • Updates
  • Investors 206
  • Discussion
  • Documents

Idea

Introduction

In 2015/16 there were 63,600 detentions under the Mental Health Act (Sections). A 47% increase over the last 10 years. There were 181,785 Deprivation of Liberty Safeguard Assessments completed in 2017/2018. An increase of 19.6% on the previous year.

Our research shows that these are still predominately paper led processes, prone to errors. Thalamos are creating an e-form & communication platform. Our objective being to speed up access to treatment and reduce errors.

Awareness of Mental Ill-Health is increasing, yet when compared to other illnesses we are still way behind with treatment solutions.

As it stands;

- Suicide has become the biggest killer of men aged 20-49 and;
- 1 in 4 of us will experience a Mental Health problem in our lives.

We think that part of the clinical challenge of managing mental ill-health is that often a number of different agencies and entities can be involved.

- The NHS.
- Social Services.
- Police and Courts.
- Charities.
- Families.
- Private Sector Providers.

Involving multiple agencies can create communication and information sharing challenges, impacting patient care.

To date Thalamos has received investment of £100,000 to fund research into these digital challenges and the technical solutions for them.

Building on this research we are now creating our first SaaS solution: Software for Psychiatrists.

Intended impact

We started Thalamos with the stated aim of empowering Psychiatrists to improve patient outcomes, particularly in non-clinical environments.

Through personal connections and personal experiences we witnessed the acute lack of digital solutions available to Doctors. More often than not, Psychiatrists are still working off paper notes.

Our subsequent focus group research has shown that Psychiatrists feel digitally under-supported when operating outside of the NHS. This lack of support is affecting:

- Clinical Decision Making.
- Information Governance.
- Continuity of Care.

Thalamos are building a secure cloud hosted platform that psychiatrists can use in the field. The aim of this platform is to enable them to:

- Reduce their clinical risk.
- Reduce their Information Governance Risk.
- Improve the continuity of care for their patients.

From this base, we believe we are perfectly placed to further solve technology challenges and in time create a digital care pathway.

Substantial accomplishments to date

- With partners MindWave we've completed focus group research with Psychiatrists from North East London Foundation (NELFT) NHS Trust and South London and Maudsley (SLAM) NHS Trust

- Leveraging this focus group research we've completed a full technical software discovery process with Helastel. Amongst their previous work Helastel have created medical grade software subsequently approved by the National Institute for Health and Care Excellence (NICE).

- Creation of a Psychiatrist led Clinical Steering Group.
The role of this group being to; advise on functionality roadmap, user experience and to form our early evangelist cohort.

- Creation of an industry specialist advisory board.
Over 40 years of experience with the likes of BUPA International, Ascribe Pharmaceutical Software, EMIS Healthcare Software and other investor and Private Equity backed businesses.

- Pre-Seed investment of £100,000 raised from professional investors.

- Arden appointed as a Development Partner with MQ Mental Health, the UK's leading Mental Health Research Charity

Monetisation strategy

The Thalamos platform will be a subscription service paid for by Psychiatrists from their Non-NHS income.

Annual subscription £600, paid monthly.

This is priced in accordance with their existing professional subscriptions:

- £450 - £624 Royal College of Psychiatry.
- £390 General Medical Council.
- £145 to £3,600 Medical Indemnity.

As with other professional expenses the fee will be tax deductible under "stationary".

Potential Ancillary Revenues:

- Training Courses.
- Private Practice referral fees.
- Accountancy referral fees.

Use of proceeds

50% Product Development

- Working with our partners to deliver our V1 product.

20% Go to Market

- Supporting Psychiatrist Training Courses.
- RCPsych Congress Exhibitor space.
- Email Marketing.

20% Working Capital

- Salaries.
- Office Costs.

10% Contingency

Using our founder investment and pre-Summer SEIS investment, we have already invested heavily in research and discovery. This means we're now ready to go. We have the team in place and the designs ready. As soon as we close the investment round we're straight into build.

From there we rapidly move towards beta testing and a full commercial launch planned for the 1st of July 2019 at the Royal College of Psychiatry International Congress.

Open an account to get access to the team members of Thalamos

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for Thalamos has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 6 December 2018 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £1,500,094

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Seedrs.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel